Skip to main content
Premium Trial:

Request an Annual Quote

The BioCommerce Week Index: Dec 8, 2005

BioCommerce Week Index of
Diversified Molecular Biology Tool Companies
Company
Ticker
Current Price
(
Dec. 6 , 2005)
Last Price
(
Nov. 29, 2005)
% Change
Agilent
A
34.94
35.49
-1.55
Applied Biosystems
ABI
27.34
27.35
-0.04
Beckman
BEC
55.73
55.63
0.18
Bio-Rad
BIO
61.19
58.43
4.72
Bruker
BRKR
5.18
4.80
7.92
Fisher Scientific
FSH
63.34
64.16
-1.28
GE
GE
35.80
35.93
-0.36
Harvard Bio
HBIO
4.51
3.66
23.22
Invitrogen
IVGN
65.60
64.50
1.71
Molecular Devices
MDCC
28.02
26.17
7.07
PerkinElmer
PKI
23.06
22.73
1.45
Qiagen
QGEN
11.36
11.17
1.70
Sigma
SIAL
65.41
66.06
-0.98
Stratagene
STGN
10.49
10.15
3.35
Thermo
TMO
31.25
30.74
1.66
Waters
WAT
38.55
39.62
-2.70
BCW Index Average  
35.11
34.79
0.93

BCW Index up Nearly One Percent as Harvard Bio Continues Climb

The BCW Index gained .9 percent for the five-day trading period ended Tuesday. Leading the gainers was Harvard Bioscience, which climbed 23.2 percent. The firm also led the Index last week with a 5.2-percent gain.

Harvard Bio's shares have been on an upward trend since mid-November, despite a lack of news from the firm. In addition, trading volume has been heavier than normal — roughly double its average over the last few days. The company announced in August that it would either sell or divest its capital equipment business, which includes the struggling Genomic Solutions business, within a year (see BioCommerce Week 8/4/2005). The firm said that it would use proceeds from the sale to pay down a $15.2 million debt facility and finance tuck-in acquisitions for the apparatus business.

In addition to Harvard Bio's jump, shares in Molecular Devices and Bruker BioSciences both rose more than 7 percent for the tracking period. Waters led decliners with a drop of 2.7 percent for the period.

In comparison to the Index, the Dow Jones Industrial Average slipped .3 percent, while the Nasdaq rose 1.3 percent, and the Nasdaq Biotech Index gained .3 percent.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.